These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 2528735

  • 1. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith PH, Suciu S.
    Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
    [No Abstract] [Full Text] [Related]

  • 2. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
    Pavone-Macaluso M, Ingargiola GB, de Voogt H, Viggiano G, Barasolo E, Lardennois B, De Pauw M, Sylvester R.
    Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
    [No Abstract] [Full Text] [Related]

  • 3. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
    Pavone-Macaluso M, Martínez-Piñeiro JA, de Voogt H, Lardennois B, Nasta A, Zolfanelli R, Barasolo E, De Pauw M, Suciu S, Sulvester R.
    Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
    [No Abstract] [Full Text] [Related]

  • 4. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S.
    Prog Clin Biol Res; 1988; 260():111-7. PubMed ID: 2966403
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The EORTC Phase III trials in prostatic cancer.
    Robinson MR, Smith PH, Macaluso MP, Sylvester R, de Voogt H.
    Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study.
    Bollack C, Rougeron G.
    Am J Clin Oncol; 1988; 11 Suppl 2():S156-9. PubMed ID: 2977270
    [Abstract] [Full Text] [Related]

  • 14. Initiation of LHRH monotherapy for prostate cancer.
    Milsted RA.
    Prog Clin Biol Res; 1989; 303():69-74. PubMed ID: 2528742
    [No Abstract] [Full Text] [Related]

  • 15. Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate.
    Robinson MR.
    Prog Clin Biol Res; 1987; 243A():383-90. PubMed ID: 2958863
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
    Schroeder FH.
    Prostate; 1984; 5(2):193-8. PubMed ID: 6231535
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.